2022 Virtual Training Course on PKPD of Protein Therapeutics, April 25-29

1 messages 1 people Latest: Jan 31, 2022
Dear Colleagues, The 2022 Virtual Introductory Training Course on 'Pharmacokinetics and Pharmacodynamics of Protein Therapeutics - Concepts and Hands-on Exercises' will be held on April 25-29, 2022. The 5-day course continues on the successful concept used in previous year offerings. It will introduce participants to basic principles in the pharmacokinetic and pharmacodynamic evaluation of novel therapeutic proteins and will provide PK and PK/PD modeling and simulation examples relevant to therapeutic proteins. Topics include target-mediated drug disposition, interspecies scaling, first-in human dose selection, model-informed drug development, pediatric pharmacology, drug-drug interactions, and immunogenicity. The target audience comprises pharmaceutical scientists from industry, academia and regulatory agencies with basic knowledge in PK and PKPD that had only limited exposure to the challenges associated with developing therapeutic proteins and that would like to receive a comprehensive overview or refresher on the PK and PKPD of this class of compounds. Although the course includes some hands-on exercises, participants do NOT need to have prior experience with any particular PKPD analysis software. For more detailed information on the preliminary course program and timing, as well as on the registration process, please visit http://www.PKPDofProteinTherapeutics.com We hope you will join us in April! The Course Directors Bernd Meibohm & Johan Gabrielsson [ https://uthsc.edu/brand/images/email-signature/shortsig-green-horizontal.png] Bernd Meibohm, PhD, FCP, FAAPS UTHSC Distinguished Professor Associate Dean for Research & Graduate Programs Chair, Department of Pharmaceutical Sciences Harriet S. Van Vleet Endowed Professor in Medicinal Chemistry and Pharmaceutics The University of Tennessee Health Science Center College of Pharmacy Pharmacy Building, Suite 435 881 Madison Avenue Memphis, TN 38163, USA [email protected]<mailto:[email protected]>